DECISION OF THE EEA JOINT COMMITTEE

No 49/2018

of 23 March 2018

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2020/66]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ('the EEA Agreement'), and in particular Article 98 thereof,

Whereas:

(1) Commission Delegated Regulation (EU) 2015/1011 of 24 April 2015 supplementing Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors, and repealing Commission Regulation (EC) No 1277/2005 ([1]), as corrected by OJ L 185, 14.7.2015, p. 31 and OJ L 125, 18.5.2017, p. 75, is to be incorporated into the EEA Agreement.

(2) Commission Implementing Regulation (EU) 2015/1013 of 25 June 2015 laying down rules in respect of Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors ([2]) is to be incorporated into the EEA Agreement.

(3) Regulation (EU) 2015/1011 repeals Commission Regulation (EC) No 1277/2005 ([3]), which is incorporated into the EEA Agreement and which is consequently to be repealed under the EEA Agreement.

(4) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XIII of Annex II to the EEA Agreement shall be amended as follows:

(1) The following is inserted after point 15x (Regulation (EC) No 273/2004 of the European Parliament and of the Council):

'15xa. **32015 R 1011**: Commission Delegated Regulation (EU) 2015/1011 of 24 April 2015 supplementing Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors, and repealing Commission Regulation (EC) No 1277/2005 (OJ L 162, 27.6.2015, p. 12), as corrected by OJ L 185, 14.7.2015, p. 31 and OJ L 125, 18.5.2017, p. 75.

The provisions of the Delegated Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The Regulation shall only apply to the EEA EFTA States with regard to Regulation (EC) No 273/2004.

([1]) OJ L 162, 27.6.2015, p. 12.
([2]) OJ L 162, 27.6.2015, p. 33.
([3]) OJ L 202, 3.8.2005, p. 7.

15xb. **32015 R 1013**: Commission Implementing Regulation (EU) 2015/1013 of 25 June 2015 laying down rules in respect of Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors (OJ L 162, 27.6.2015, p. 33).

The provisions of the Implementing Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The Regulation shall only apply to the EEA EFTA States with regard to Regulation (EC) No 273/2004.'

(2) The text of point 15ze (Commission Regulation (EC) No 1277/2005) is deleted.

Article 2

The texts of Delegated Regulation (EU) 2015/1011, as corrected by OJ L 185, 14.7.2015, p. 31 and OJ L 125, 18.5.2017, p. 75, and Implementing Regulation (EU) 2015/1013 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 24 March 2018, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 23 March 2018.

For the EEA Joint Committee
The President
Claude MAERTEN

(*) No constitutional requirements indicated.